# Belite Bio, Inc (BLTE) insider trading

> In the 12 months to Oct 31, 2026, 5 BLTE insiders reported open-market sales of $40.6M across 27 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/blte/insider-trading
Latest filing: 2026-10-30 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $40.6M | 27 filings · 5 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 25 of 27 | $37.8M of $40.6M sold (93%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Yu-Hsin Lin | Chief Executive Officer | $20.8M | — | 3 | 100% of sales | 2026-09-09 |
| Hao-Yuan Chuang | Chief Financial Officer | $14.0M | — | 3 | 100% of sales | 2026-09-09 |
| Hendrik Peter Scholl | Chief Medical Officer | $2.9M | — | 3 | 3% of sales | 2026-10-05 |
| Nathan L. Mata | Chief Scientific Officer | $2.7M | — | 17 | 100% of sales | 2026-05-08 |
| Wan-Shan Chen | Director | $198.5K | — | 1 | 100% of sales | 2026-04-13 |

## Open-market trades by filing

27 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-10-05 | 2026-10-01 | Hendrik Peter Scholl | Chief Medical Officer | Sale (10b5-1) | 500 | $165.32 | $82.7K | 14,516 | — |
| 2026-09-09 | 2026-09-04 | Hao-Yuan Chuang | Chief Financial Officer | Sale (10b5-1) | 67,395 | $189.98 | $12.8M | 26,038 | — |
| 2026-09-09 | 2026-09-04 | Yu-Hsin Lin | Chief Executive Officer | Sale (10b5-1) | 100,435 | $190.00 | $19.1M | 93,734 | — |
| 2026-08-14 | 2026-08-12 | Yu-Hsin Lin | Chief Executive Officer | Sale (10b5-1) | 365 | $180.35 | $65.8K | 170,569 | — |
| 2026-08-14 | 2026-08-12 | Hao-Yuan Chuang | Chief Financial Officer | Sale (10b5-1) | 367 | $180.35 | $66.2K | 93,433 | — |
| 2026-06-22 | 2026-06-18 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 10,000 | $145.24 | $1.5M | 15,000 | — |
| 2026-06-17 | 2026-06-16 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 10,000 | $140.57 | $1.4M | 25,000 | — |
| 2026-05-08 | 2026-05-07 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 666 | $153.21 | $102.0K | 12 | — |
| 2026-05-07 | 2026-05-06 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $153.84 | $153.8K | 866 | — |
| 2026-05-06 | 2026-05-05 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $155.50 | $155.5K | 2,546 | — |
| 2026-05-05 | 2026-05-04 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $155.64 | $155.6K | 3,398 | — |
| 2026-05-04 | 2026-05-01 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $155.78 | $155.8K | 3,980 | — |
| 2026-05-01 | 2026-04-30 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $156.97 | $157.0K | 5,624 | — |
| 2026-04-30 | 2026-04-29 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $155.82 | $155.8K | 6,388 | — |
| 2026-04-29 | 2026-04-28 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $159.16 | $159.2K | 6,929 | — |
| 2026-04-28 | 2026-04-27 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $162.64 | $162.6K | 8,111 | — |
| 2026-04-27 | 2026-04-24 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $159.56 | $159.6K | 8,666 | — |
| 2026-04-24 | 2026-04-23 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $166.28 | $166.3K | 10,399 | — |
| 2026-04-23 | 2026-04-22 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $170.38 | $170.4K | 11,373 | — |
| 2026-04-22 | 2026-04-21 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $166.00 | $166.0K | 12,192 | — |
| 2026-04-21 | 2026-04-20 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $163.59 | $163.6K | 12,666 | — |
| 2026-04-20 | 2026-04-16 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $160.38 | $160.4K | 15,030 | — |
| 2026-04-20 | 2026-04-17 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $161.63 | $161.6K | 14,582 | — |
| 2026-04-16 | 2026-04-15 | Nathan L. Mata | Chief Scientific Officer | Sale (10b5-1) | 1,000 | $168.30 | $168.3K | 16,283 | — |
| 2026-04-13 | 2026-04-09 | Hao-Yuan Chuang | Chief Financial Officer | Sale (10b5-1) | 6,200 | $181.50 | $1.1M | 94,091 | — |
| 2026-04-13 | 2026-04-09 | Wan-Shan Chen | Director | Sale (10b5-1) | 1,100 | $180.43 | $198.5K | 9,096 | — |
| 2026-04-13 | 2026-04-09 | Yu-Hsin Lin | Chief Executive Officer | Sale (10b5-1) | 9,200 | $181.45 | $1.7M | 174,134 | — |

## Other insider activity (not market trades)

- Other: 5 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has Belite Bio, Inc's CEO sold stock?

Yes. Yu-Hsin Lin (CEO) sold 110,000 shares ($20.8M) between Apr 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan.

### How current is BLTE’s insider data?

These are BLTE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The BLTE Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=BLTE&filing_date.gte=2025-10-31&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Belite Bio, Inc (BLTE) stock price](https://massive.com/quote/blte.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms